Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?

Author(s): G. Ali Qureshi, Aftab A. Qureshi, Bika Ram Devrajani, M. A. Chippa, S. Ali Syed

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 7 , Issue 1 , 2008

Become EABM
Become Reviewer
Call for Editor


This review deals with the results showing the relation between vitamin B12 deficiency and neurotoxicity of homocysteine and nitrite (a metabolite of nitric oxide) in Parkinsons patients treated with levodopa (L-Dopa). We have already reported a linear relationship between the CSF levels of nitrite with glutamic acid and homocysteine suggesting that the production of nitrite is interrelated with the neurotoxic level of homocysteine. The levels of nitrite and homocysteine resulting in the deficiency of vitamin B12 are some of the factors promoting degeneration in Parkinsons disease. This review emphasizes the importance of these parameters in designing suitable drug therapy for Parkinson disease. Additionally, there is evidence that increased homocysteine levels might accelerate dopaminergic cell death in Parkinson disease (PD), through neurotoxic effects. Furthermore, levodopa (L-Dopa) treatment of PD results in hyperhomocysteinemia as a consequence of L-Dopa methylation by catechol-O-methyltransferase (COMT). Therefore, higher dietary intakes of folate, vitamin B12, and vitamin B6 might decrease the risk of PD through decreasing plasma homocysteine.

Keywords: Cerebrospinal fluid, vitamin B12, homocysteine, nitrite, Parkinson's disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [20 - 27]
Pages: 8
DOI: 10.2174/187152708783885101
Price: $65

Article Metrics

PDF: 48